MP36-02 TESTOSTERONE (T) RECOVERY PROFILES AFTER SHORT-TERM ANDROGEN DEPRIVATION THERAPY (ADT)

Abstract

Listen

Translate article

You have accessJournal of UrologySexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy II (MP36)1 Sep 2021MP36-02 TESTOSTERONE (T) RECOVERY PROFILES AFTER SHORT-TERM ANDROGEN DEPRIVATION THERAPY (ADT) Jose M Flores, Bruno Nascimento, Nicole Benfante, Elizabeth Schofield, and John P Mulhall Jose M FloresJose M Flores More articles by this author , Bruno NascimentoBruno Nascimento More articles by this author , Nicole BenfanteNicole Benfante More articles by this author , Elizabeth SchofieldElizabeth Schofield More articles by this author , and John P MulhallJohn P Mulhall More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002045.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: ADT plays a major role in several scenarios for men with prostate cancer. T recovery after ADT cessation may be incomplete with 10% of men estimated to suffer persistent castrate levels after long-term ADT. The objective of this study was to evaluate T recovery after short courses of ADT. METHODS: Study population included men treated with ≤6 months of ADT in association with radiation therapy (RT). Early morning T levels were collected at baseline and periodically after ADT cessation. T recovery after ADT cessation was analyzed in 2 ways: improvement to non-castrate level (T≥50 ng/dL), and recovery to normal (T≥300 ng/dL). Recovery rates and median survival time were estimated using Kaplan-Meier statistics and predictors analyzed using Cox proportional hazard ratios. RESULTS: 88 men with a mean age of 68±8 years at time of ADT were analyzed. Median duration of ADT was 3.1 months; 56% had an ADT duration between 1-3 months and 44% between 4-6 months. Mean pre-ADT T level was 390±158 ng/dL. After cessation of ADT, median time to non- castrate levels was 9.3 (IQR=6.3–18.5) months and 15.8 (IQR=8.3-33.8) `months for recovery to T≥300 ng/dL. Higher baseline T levels (T>400 ng/dL) was associated with a faster recovery to normal T level (HR=1.80, 95% CI=1.09–2.95), but not to non-castrate level. Neither age >65 years, prevalent diabetes, nor ADT duration of 4-6 months vs ≤3 months were significantly associated with a slower T recovery. CONCLUSIONS: Most of our patients remained with low T levels one year after the cessation of ADT. Higher baseline T was associated with faster T recovery to normal (T≥300 ng/dL). Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e636-e636 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jose M Flores More articles by this author Bruno Nascimento More articles by this author Nicole Benfante More articles by this author Elizabeth Schofield More articles by this author John P Mulhall More articles by this author Expand All Advertisement Loading ...